These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
783 related articles for article (PubMed ID: 20359812)
1. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812 [TBL] [Abstract][Full Text] [Related]
2. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453 [TBL] [Abstract][Full Text] [Related]
3. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. Leibovich BC; Sheinin Y; Lohse CM; Thompson RH; Cheville JC; Zavada J; Kwon ED J Clin Oncol; 2007 Oct; 25(30):4757-64. PubMed ID: 17947723 [TBL] [Abstract][Full Text] [Related]
4. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials. Zhou GX; Ireland J; Rayman P; Finke J; Zhou M Urology; 2010 Feb; 75(2):257-61. PubMed ID: 19963243 [TBL] [Abstract][Full Text] [Related]
5. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up. Zhang BY; Thompson RH; Lohse CM; Dronca RS; Cheville JC; Kwon ED; Leibovich BC BJU Int; 2013 Jun; 111(7):1046-53. PubMed ID: 23551810 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature. Zhao Z; Liao G; Li Y; Zhou S; Zou H; Fernando S PLoS One; 2014; 9(11):e114096. PubMed ID: 25426861 [TBL] [Abstract][Full Text] [Related]
7. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). Choueiri TK; Cheng S; Qu AQ; Pastorek J; Atkins MB; Signoretti S Urol Oncol; 2013 Nov; 31(8):1788-93. PubMed ID: 23141780 [TBL] [Abstract][Full Text] [Related]
8. Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. Al-Ahmadie HA; Alden D; Qin LX; Olgac S; Fine SW; Gopalan A; Russo P; Motzer RJ; Reuter VE; Tickoo SK Am J Surg Pathol; 2008 Mar; 32(3):377-82. PubMed ID: 18300814 [TBL] [Abstract][Full Text] [Related]
9. Identification and validation of novel prognostic markers in Renal Cell Carcinoma. Rabjerg M Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma. Phuoc NB; Ehara H; Gotoh T; Nakano M; Kamei S; Deguchi T; Hirose Y Oncol Rep; 2008 Sep; 20(3):525-30. PubMed ID: 18695901 [TBL] [Abstract][Full Text] [Related]
11. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Patard JJ; Fergelot P; Karakiewicz PI; Klatte T; Trinh QD; Rioux-Leclercq N; Said JW; Belldegrun AS; Pantuck AJ Int J Cancer; 2008 Jul; 123(2):395-400. PubMed ID: 18464292 [TBL] [Abstract][Full Text] [Related]
12. Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Oosterwijk-Wakka JC; Boerman OC; Mulders PF; Oosterwijk E Int J Mol Sci; 2013 May; 14(6):11402-23. PubMed ID: 23759990 [TBL] [Abstract][Full Text] [Related]
13. Carbonic anhydrase IX as a specific biomarker for clear cell renal cell carcinoma: comparative study of Western blot and immunohistochemistry and implications for diagnosis. Giménez-Bachs JM; Salinas-Sánchez AS; Serrano-Oviedo L; Nam-Cha SH; Rubio-Del Campo A; Sánchez-Prieto R Scand J Urol Nephrol; 2012 Oct; 46(5):358-64. PubMed ID: 22571179 [TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. Büscheck F; Fraune C; Simon R; Kluth M; Hube-Magg C; Möller-Koop C; Shadanpour N; Bannenberg C; Eichelberg C; Höflmayer D; Clauditz T; Wittmer C; Wilczak W; Sauter G; Fisch M; Rink M; Eichenauer T Urol Oncol; 2018 Dec; 36(12):531.e19-531.e25. PubMed ID: 30322727 [TBL] [Abstract][Full Text] [Related]
15. [Value of MN/CAIX in the diagnosis of renal cell carcinoma]. Jiang YD; Ren F; Zheng SB Nan Fang Yi Ke Da Xue Xue Bao; 2012 Mar; 32(3):412-4. PubMed ID: 22445996 [TBL] [Abstract][Full Text] [Related]
16. [Expression of carbonic anhydrase IX, PAX2 and PAX8 and their association with clinicopathologic characteristics in renal epithelial tumors]. Zhang W; Yu WJ; Xia Y; Liu Y; Liu XL; Zhuang J; Li YJ Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):442-5. PubMed ID: 24246861 [TBL] [Abstract][Full Text] [Related]
17. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Cho D; Signoretti S; Dabora S; Regan M; Seeley A; Mariotti M; Youmans A; Polivy A; Mandato L; McDermott D; Stanbridge E; Atkins M Clin Genitourin Cancer; 2007 Sep; 5(6):379-85. PubMed ID: 17956710 [TBL] [Abstract][Full Text] [Related]
18. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT. Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. Bui MH; Visapaa H; Seligson D; Kim H; Han KR; Huang Y; Horvath S; Stanbridge EJ; Palotie A; Figlin RA; Belldegrun AS J Urol; 2004 Jun; 171(6 Pt 1):2461-6. PubMed ID: 15126876 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical Panel for Differentiating Renal Cell Carcinoma with Clear and Papillary Features. Alshenawy HA Pathol Oncol Res; 2015 Sep; 21(4):893-9. PubMed ID: 25712789 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]